20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial – Journal of Clinical Oncology

News Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet

Commentary on Twitter

20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA

— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022